Pharmacologic therapy for diabetic retinopathy

Expert Opinion on Emerging Drugs

Volumn 8, Issue 1, 2003, Pages 239-250

  Speicher, Matthew A ^a   Danis, Ronald P ^a   Criswell, Mark ^a   Pratt, Linda ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; IGF 1; Integrins; Macular oedema; Neovascularisation; PKC; Proliferative diabetic retinopathy; Steroids; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANECORTAVE; ANGIOGENESIS INHIBITOR; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; CANDESARTAN HEXETIL; FLUOCINOLONE ACETONIDE; HORMONE ANTAGONIST; HYALURONIDASE; ISIS 107189; LY 33353; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; OCTREOTIDE; PIGMENT EPITHELIUM DERIVED FACTOR; PRINOMASTAT; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXAMINE; RECOMBINANT HUMANIZED VASCULOTROPIN MONOCLONAL ANTIBODY FRAGMENT; RUBOXISTAURIN; SOMATOMEDIN C ANTAGONIST; STEROID; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN C MONOCLONAL ANTIBODY; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; BLEEDING; BLINDNESS; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LASER SURGERY; NONHUMAN; PREVALENCE; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA SURGERY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STEROID THERAPY; SUBRETINAL NEOVASCULARIZATION; SUSTAINED RELEASE PREPARATION; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENESIS INHIBITORS; ANIMALS; DIABETIC RETINOPATHY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0038318790     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.1.239     Document Type: Review

References (109)

1. KLEIN R: The epidemiology of diabetic eye disease. In: Textbook of diabetes. Pickup J & Williams G (Eds) Blackwell Science, Oxford (1997):44.1-44.9.
2. D'AMICO DJ: Diseases of the retina. N. Engl. J. Med. (1994) 331:95-106.
3. BARRY P: The management of diabetic eye disease. In: Textbook of diabetes. Pickup J & Williams G (Eds) Blackwell Science, Oxford (1997):47.41-47.42.
4. FINE SL, PATZ A: Ten years after the Diabetic Retinopathy Study. Surv. Ophthalmol. (1987) 94:739-740.
5. KLEIN R, KLEIN BE, MOSS SE, CRUICKSHANKS KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long-term incidence of macular edema. Ophthalmology (1995) 102:7-16.
6. NO AUTHORS LISTED: Photocoagulation for diabetic macular edema; early treatment diabetic retinopathy study report number 1. Early Treatment of Diabetic Retinopathy Study Group. Arch. Ophthalmol. (1985) 103:1796-1806.
7. ANTONELLI-ORLIDGE A, SMITH S, D'AMORE P: Influence of pericytes on capillary endothelial cell growth. Am. Rev. Respir. Dis. (1989) 140:1129-1131.
8. CAMPOCHIARO PA: Retinal and choroidal neovascularization. J. Cell Physiol. (2000) 184:301-310. An excellent in-depth review of angiogenesis mechanisms and some therapeutic options.
9. NO AUTHORS LISTED: Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Diabetic Retinopathy Study Group. Surv. Ophthalmol. (1978) 85:82-106. A classic report of the DRS.
10. NO AUTHORS LISTED: Proliferative diabetic retinopathy: treatment with xenonarc photocoagulation. Interim report of multicentre randomized controlled trial. British Multicentre Trial of Photocoagulation. Br. Med. J. (1977) 1:739-741.
11. SMIDDY WE: Vitrectomy for complications of diabetic retinopathy. Int. Ophthalmol. Clin. (1998) 38:155-167.
12. FERRIS FL: How effective are treatments for diabetic retinopathy? JAMA (1993) 269:1290-1291. An outline of epidemiological aspects and laser treatment of diabetic retinopathy with respect to societal costs.
13. MUKAMEL DB, BRESNICK GH, WANG Q, DICKEY CF: Barriers to compliance with screening guidelines for diabetic retinopathy. Ophthalmic Epidemiol. (1999) 6:61-72.
14. NO AUTHORS LISTED: Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy study report no. 5. Diabetic Retinopathy Study Group. Dev. Ophthalmol. (1981) 2:248-261.
15. COLWELL JA: Intensive insulin therapy in Type II diabetes: rationale and collaborative clinical trial results. Diabetes (1996) 45(Suppl. 3):S87-S90. Good overview of clinical trials of glycaemic control.
16. TURNER RC: The UK Prospective diabetes study. A review. Diabetes Care (1998) 21(Suppl. 3):C35-C38.
17. NO AUTHRS LISTED: The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Diabetes Complications And Control Trial Study Group. Arch. Ophthalmol. (1995) 113:36-51.
18. ENGERMAN RL, KERN T: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes (1987) 36:808-812. A classic animal study elucidating some aspects of the pathophysiology of diabetic retinopathy.
19. NO AUTHORS LISTED: Early worsening of diabetic retinopathy in the diabetes control and complications trial. The Diabetes Control And Complications Trial Research Group. Arch. Ophthalmol. (1998) 116:874-886.
20. NO AUTHORS LISTED: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br. Med. J. (1998) 317:703-713.
21. NO AUTHORS LISTED: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS 39. UK Prospective Diabetes Study Group. Br. Med. J. (1998) 317:713-720.
22. DANSER AHJ, VAN DEN DORPEL MA, DEINUM J et al.: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. (1989) 68:160-167.
23. DANSER AHJ, DERKX FH, ADMIRAAL PJ et al.: Angiotensin levels in the eye. Invest. Ophthalmol. Vis. Sci. (1994) 35:1008-1018.
24. FUNATSU H, YAMASHITA H, IKEDA T, NAKANISHI Y, KITANO S, HORI S: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am. J. Ophthalmol. (2002) 133:537-543.
25. HOGEBOOM VAN BUGGENUM IM, POLAK BC, REICHERT-THOEN JW, DE VRIES-KNOPPERT WA, VAN HINSBERGH VW, TANGELDER GJ: Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia (2002) 45:203-209.
26. CHATURVEDI N, FULLER JH, POKRAS F, ROTTIERS R, PAPAZOGLOU N, AIELLO LP: Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition. Euclid Study Group. Diabet. Med. (2001) 18:288-294.
27. NAGISA Y, SHINTANI A, NAKAGAWA S: The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetalogia (2001) 44:883-888.
28. CHATURVEDI N, SJOELIE AK, SVENSSON A: The diabetic retinopathy candesartan trials (DIRECT) programme, rationale and study design. The Direct Programme Study Group. Renin Angiotensin Aldosterone Syst. (2002) 3:255-261.
29. KINOSHITA JH: Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture. Am. J. Ophthalmol. (1986) 102:685-692.
30. ROBISON W: Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors. Adv. Exp. Med Biol. (1988) 286:365-372.
31. NARUSE K, NAKAMURA J, HAMADA Y et al.: Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp. Eye Res. (2000) 71:309-315.
32. NO AUTHORS LISTED: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Study Group. Arch. Ophthalmol. (1990) 108:1234-1244.
33. PFEIFER MA, SCHUMER MP, GELBER DA: Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes (1997) 46(Suppl. 2):S82-S89.
34. VLASSARA H: Recent progress in advanced glycation end products and diabetic complications. Diabetes (1997) 46(Suppl. 2):S19-S25. Thorough overview of the biochemistry of AGE production and cell effects.
35. BAYNES JW, THORPE SR: Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. (2000) 28:1708-1716.
36. KERN TS, TANG J, MIZUTANI M et al.: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest. Ophthalmol. Vis. Sci. (2000) 41:3972-3978.
37. STITT A, GARDINER TA, ANDERSON NL et al.: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes (2002) 51:2826-2832.
38. KOWLURU RA, TANG J, KERN TS: Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes (2001) 50:1938-1942.
39. TAKAHASHI T, UENO H, SHIBUYA M: VEGF activates protein kinase C-dependent, but ras-independent raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene (1999) 18:2221-2230.
40. SCIVITTARO V, GANZ MB, WEISS MF: AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am. J. Physiol. Renal physiol. (2000) 278:F676-F683.
41. KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47:859-866.
42. KOWLURU RA, JIROUSEK MR, STRAMM L et al.: Abnormalities of retinal metabolism in diabetes or experimental galactosemia. Diabetes (1998) 47:464-469.
43. CHEN S, COHEN MP, ZIYADEH FN: Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int. (2000) 58(Suppl. 77):S40-S44.
44. GARDNER TW, ANTONETTI DA, BARBER AJ, LANOUE KF, LEVISON SW: Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. (2002) 47(Suppl. 2):S253-S262. Excellent review of recent observations regarding cellular anatomy contributing to the BRB.
45. GILBERT RE, VRANES D, BERKA JL et al.: Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab. Invest. (1998) 78:1017-1027.
46. QAUM T, XU Q, JOUSSEN AM et al.: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. (2001) 42:2408-2413.
47. POULAKI V, QIN W, JOUSSEN AM et al.: Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J. Clin. Invest. (2002) 109:805-815.
48. AIELLO LP, BURSELL SE, CLERMONT A et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes (1997) 46:1473-1480. First use of a selective PKC inhibitor to explore ocular physiology in an animal model of diabetes.
49. ANTONETTI DA, BARBER AJ, KHIN S, LIETH E, TARBELL JM, GARDNER TW: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes (1998) 47:1953-1959.
50. ANTONETTI DA, WOLPERT EB, DEMAIO L, HARHAJ NS, SCADUTO RC: Hydroxortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. (2002) 80:667-677.
51. FOLKMAN J: Angiogenesis: initiation and control. Ann. NY Acad. Sci. (1982) 401:212-227. A classic report of fundamental aspects of angiogenesis.
52. SEBAG J: Pharmacologic vitreolysis. Retina (1998) 18:1-3.
53. KUPPERMAN B, THOMAS E, GRAUE M et al.: Clearance of vitreous hemorrhage after intravitreal administration of hyaluronidase: Preclinical pharmacology and clinical outcomes. ARVO Annual Meeting Fort Lauderdale, FL, USA (2000):S347.
54. GRAUE-WIECHERS F, DELGADILLO A, QUIROZ-MERCADO H et al.: Pharmacologic induction of a posterior vitreous detachment in human diabetic eyes treated with purified ovine hyaluronidase. American Academy of Ophthalmology Annual Meeting. Dallas, TX, USA (2000):99.
55. SIMO R, LECUBE A, SEGURA RM, GARCIA ARUMI J, HERNANDEZ C: Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. (2002) 134:376-382.
56. MILLER J, ADAMIS A, SHIMA D et al.: Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. (1994) 145:574-584.
57. ADAMIS AP, SHIMA DT, TOLENTINO MJ et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. (1996) 114:66-71. First use of a VEGF inhibitor to treat ocular angiogenesis.
58. SCHLAEPPI JM, WOOD JM: Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev. (1999) 18:473-481.
59. MELLO L, NORTHRUP J, KEYT B, TAKAGI H, IWAMOTO M: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalmol. (1995) 113:1538-1544.
60. ROBINSON GS, PIERCE EA, ROOK SL et al.: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. USA (1996) 93:4851-4856. First use of antisense technology to treat intraocular angiogenesis.
61. HONDA M, SAKAMOTO T, ISHIBASHI T, INOMATA H, UENO H: Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther. (2000) 7:978-985. First use of gene transfer technology to treat intraocular angiogenesis.
62. NO AUTHORS LISTED: Preclinical and Phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. The Eyetech Study Group. Retina (2002) 22:143-152.
63. BREKKEN RA, OVERHOLSER JP, STASTNY VA et al.: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (kdr/fik-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. (2000) 60:5117-5124.
64. WEDGE SR, OGILVIE DJ, DUKES M et al.: Zd4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. (2000) 60:970-975.
65. KWAK N, OKAMOTO N, WOOD JM, CAMPOCHIARO PA: VEGF is major stimulator in model of choroidal neovascularizaion. Invest. Ophthalmol. Vis. Sci. (2000) 41:3158-3164.
66. CARTER SK: Clinical strategy for the development of angiogenesis inhibitors. Oncologist (2000) 5:51-54. A good review of angiogenesis inhibition strategies in relation to tumour growth.
67. SMITH LE, KOPCHICK JJ, CHEN W et al.: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science (1997) 276:1706-1709. A particularly elegant report illustrating the interdependence of VEGF and IGF-1 in angiogenesis in the eye.
68. SMITH LE, SHEN W, PERRUZZI C et al.: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med. (1999) 5:1390-1395.
69. PFEIFFER A, SPRANGER J, MEYER-SCHWICKERATH R, SCHATZ H: Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes (1997) 46(Suppl. 2):S26-S30.
70. DANIS RP, BINGAMAN DP, YANG Y, LEE W: Chronic upregulation of components of the IGF-1 system after a single intravitreal injection of hrIGF-1 in pigs. Invest. Opthalmol. Vis. Sci. (1996) 37(Suppl.):S203.
71. YAMADA H, YAMADA E, ANDO A et al.: Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy. Am. J. Pathol. (2000) 156:477-487.
72. DANIS RP, BINGAMAN DP: Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology (1997) 104(10):1661-1669.
73. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. (1998) 12:149-162.
74. KING GL, GOODMAN AD, BUZNEY S, MOSES A, KAHN CR: Receptors and growth-promoting effects of insulin and insulin like growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest. (1985) 75:1028-1036.
75. MERIMEE T: A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N. Engl. J. Med. (1978) 298(22):1217-1222.
76. KOHNER EM, HAMILTON AF, JOPLIN GF: Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation. Diabetes (1976) 25:104-110.
77. CHEN T, MILLER TF, PRASAD P et al.: Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J. Clin. Pharmacol. (2000) 40:475-481.
78. BOEHM BO, LANG GK, JEHLE PM, FELDMAN B, LANG GE: Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm. Metab. Res. (2001) 33:300-306.
79. GRANT MB, MAMES RN FITZGERALD C et al.: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diab. Care (2000) 23:504-509. The first clinical of a somatostatin analogue for PDR.
80. STELLMACH V, CRAWFORD SE, ZHOU W, BOUCK N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. USA (2001) 98:2122-2124.
81. MORI K, GEHLBACH P, ANDO A, MCVEY D, WEI L, CAMPOCHIARO PA: Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. (2002) 43:2428-2434.
82. YAMAGASHI S, INAGAKI Y, AMANO S, OKAMOTO T, TAKEUCHI M, MAKITA Z: Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun. (2002) 296:877-882.
83. OGATA N, TOMBRAN-TINK J, JO N, MRAZEK D, MATSUMURA M: Upregulation of pigment epithelium-derived factor after laser photocoagulation. Am. J. Ophthalmol. (2001) 132:427-429.
84. FRIEDLANDER M, BROOKS P, SHAFFER R et al.: Definition of two angiogenic pathways by distinct alpha v integrins. Science (1995) 270:1500-1502. An elegant study illustrating some important aspects of intracellular signal transduction via integrins.
85. LUNA J, TOBE T, MOUSA SA, REILLY TM, CAMPOCHIARO PA: Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab. Invest. (1996) 75:563-573.
86. HAMMES HP, BROWNLEE M, JONCZYK A, SUTTER A, PREISSNER KT: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. (1996) 2:529-533.
87. NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN LM: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. (2000) 18:1135-1149. In-depth review of this class of antiangiogenic agents.
88. ABU EL-ASRAR AM, DRALANDS L, VECKENEER M et al.: Gelatinase B in proliferative vitreoretinal disorders. Am. J. Ophthalmol. (1998) 125:844-851.
89. DAS A, MCGUIRE PG, ERIQAT C et al.: Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest. Ophthalmol. Vis. Sci. (1999) 40:809-813.
90. KOSANO H, OKANO T, KATSURA Y et al.: ProMMP-9 (92 kda gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci. (1999) 64:2307-2315.
91. DAHL-JORGENSEN K: Diabetic microangiopathy. Acta Paediatr. Suppl. (1998) 425:31-34.
92. GARCIA C, BARTSCH D, RIVERO M et al.: Efficacy of prinomastat® (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr. Eye Res. (2002) 24:33-38.
93. FOLKMAN J, INGBER D: Angiostatic steroids. Ann. Surg. (1987) 206:374-382. A classic report.
94. INGBER D, MADRI J, FOLKMAN J: A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology (1986) 119:1768-1775.
95. DANIS RP, BINGAMAN DP, YANG Y, LADD L: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology (1996) 103:2099-2104.
96. ROTSCHILD T, NANDGAONKAR BN, YU K, HIGGINS RD: Dexamethasone reduces oxygen induced retinopathy in a mouse model. Pediatr. Res. (1999) 46:94-100.
97. CIULLA TA, CRISWELL MH, DANIS RP, HILL TE: Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol. (2001) 119:399-404.
98. MARTIDIS A, MILLER DG, CIULLA TA, DANIS RP, MOORTHY RS: Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J. Ocul. Pharmacol. Ther. (1999) 15:425-428.
99. DANIS RP, CIULLA TA, PRATT LM, ANLIKER W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina (2000) 20:244-250.
100. MARTIDIS A, NELSON ML, BAKER B et al.: Intravitreal triamcinolone for refractory diabetic macular edema. Vitreous Society Annual Meeting, San Francisco, CA, USA (2002):144-145.
101. PEARSON P, ABOU-JAOUDE E, SMITH T, ASHTON P: A Phase I evaluation of sustained delivery fluocinolone in the treatment of diabetic macular edema. American Academy of Ophthalmology Annual Meeting, Dallas, TX, USA (2000):99.
102. TERUO S, INOGUCHI T, SPORTSMAN JR et al.: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol. (1993) 265:E783-E793.
103. TRANQUE PA, CALLE R, NAFTOLIN F, ROBBINS R: Involvement of protein kinase-C in the mitogenic effect of insulin-like growth factor-1 on rat astrocytes. Endocrinology (1992) 131:1948-1954.
104. INOGUCHI T, BATTAN R, HANDLER E et al.: Preferential elevation of protein kinase C beta II isoform and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibiliry to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. USA (1992) 88:11059-11068.
105. SEO MS, KWAK N, OZAKI H et al.: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol. (1999) 154:1743-1753.
106. JIROUSEK MR, GILLIG JR, GONZALEZ CM et al.: S-13-[(dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1h, 13h-dibenzo[e,k] pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2h)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J. Med. Chem. (1996) 39:2664-2671. Detailed report of a highly selective PKC beta II inhibitor.
107. DANIS RP, BINGAMAN DP, JIROUSEK M, YANG Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest. Ophthalmol. Vis. Sci. (1998) 39:171-179.
108. HAYASHI A, KIM H, DE JUAN E JR: Alterations in protein tyrosine kinase pathways following retinal vein occlusion in the rat. Curr. Eye Res. (1999) 18:231-239.
109. DANIS R, CRISWEL M, ORGE F, MONIA B, HENRY S: Angioinhibitory action of intravitreous anti-raf-1 kinase antisense oligonucleotide in the pig BVO model. Curr. Eye Res. (2003) (in press).